Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMX-110 + Tislelizumab in advanced solid tumors
NCT05840835Phase 2Unknown
- Sponsor
- Immix Biopharma
- Start
- Feb 2023
- Primary completion
- Jan 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of IMX-110 in solid tumor (advanced stage), sponsored by Immix Biopharma. Status: unknown.
02
Drugs
IMX-110
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05840835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05840835.